Drugs / INV-202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05282446 | Mar → Sep 2022 | metabolic syndrome X | Inversago Pharma Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-20 | Novo Nordisk A/S | Results Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed novonordisk.com ↗
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-20 | Novo Nordisk A/S | Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed novonordisk.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INV-202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05282446 ↗ |
| Route | Oral | “INV-202 25mg by mouth once daily” NCT05282446 ↗ |